Market Overview

WuXi AppTec Research Service Division and Cyclica Collaborate to Drive Polypharmacology in Drug Discovery Through AI-Augmented Technologies

Share:

WuXi AppTec Research Service Division (www.wuxiapptec.com),
and Cyclica (www.cyclicarx.com)
are pleased to announce a multi-phase collaboration to advance drug
discovery programs by driving insights into small molecule
polypharmacology, while further evolving Cyclica's biophysics and
AI-augmented platform.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180816005142/en/

Through a multi-phase collaboration, WuXi will leverage and evaluate
Cyclica's cloud-based proteome Ligand Express™ screening platform to
investigate the off-target profiles of small molecules, apply Cyclica's
novel and proprietary advanced AI technology to create state of the art
predictive models for ADMET properties, and support the testing and
optimization of Cyclica's next generation AI-based de novo drug
design technology.

Dr. Dave Madge, Vice President, Research Services Division at WuXi
AppTec, commented, "WuXi is on the cutting edge of integrating and
leveraging innovative AI solutions in our capability platform, to
streamline and create productivity in drug discovery. What makes
Cyclica's value proposition unique is that they offer enabling solutions
at various points across the value chain which we believe will help us
take further steps in the right direction. We are excited to apply,
evaluate, and support the growth of their technologies, and assess how
they fit in our overall strategy to advance pre-clinical success."

Naheed Kurji, President and CEO of Cyclica said, "Over the past two
years, we've built a strong relationship with the world-class team at
WuXi, and we are thrilled to work closely and collaborate with them to
advance our shared interests. For Cyclica, this represents an incredible
opportunity to continue to drive our innovation plans, while gaining
insights and validation from a market leader. This collaboration will
enable Cyclica to advance our vision of enabling bench scientists with
an intuitive and easy to use cloud-based platform that is built around
an integrated network of technologies that support the design,
screening, and stratification of better drugs."

About Cyclica:

Cyclica is a Toronto-based biotechnology company that is driving drug
discovery by empowering scientists in pharma with an integrated
cloud-based and AI-augmented platform that enhances how they design,
screen and personalize medicines. To learn more, visit www.cyclicarx.com.

View Comments and Join the Discussion!